Amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND) is a relatively common neurodegenerative condition with a prevalence of approximately 5 per 100 000 and is characterised by loss of motor neurones in the spinal cord, brain stem, and motor cortex. Approximately 5 to 10% of ALS cases are familial. The familial form is indistinguishable from the sporadic form with a mean age of onset of 50 years and a rapid progression of approximately three years duration. Recently, mutations in Cu/Zn superoxide dismutase (SOD-1) have been identified in a subpopulation of familial cases and this has stimulated an enormous amount of interest. This finding has opened the way to investigating potential pathogenic mechanisms and developing treatment rationales. However, the picture is still incomplete as SOD-1 mutations have only been detected in a minority of cases (fig 1) and the value of identifying subjects at risk in the subgroup is debatable. The aim of this review is to provide a summary of the most recent developments in FALS research which give an insight into the possible mechanisms underlying the disease and their implications and expectations for affected subjects.
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Clinical and pathological features of FALS PHENOTYPIC HETEROGENEITY AND SIMILARITIES WITH SPORADIC ALS
Familial ALS (FALS) is expressed as an age dependent autosomal dominant trait. There is incomplete penetrance being 0-8 at the age of 85 years. It is therefore not uncommon to see obligate carriers in a family who die without manifesting the disease (see pedigrees 5, 6 , and 7, fig 2) . The phenotypic heterogeneity seen in sporadic forms of ALS are also common within families, for example, age of onset may vary over 30 years within a family as can duration of illness (for example, 0 5 to 5 years) and signs at onset. The initiation of the disease is usually focal and asymmetrical, for example, wasting of muscles of one hand, and then spreads in a contiguous way. Lower motor neurone involvement is usually conspicuous in most cases whereas involvement of upper motor neurones is less marked. Pathologically, the disease starts A patient with a familial form of ALS will be clinically indistinguishable from one with the sporadic form. 8 The diagnosis ofALS is based on the clinical history and findings on examination and may be supported by electrophysiological and imaging studies which may also exclude other potentially treatable conditions. The disease is progressive, resulting in death in 50% of patients within three years of onset. A proportion of patients have a much more protracted course, over decades. Significant disability and dependence may result in the later stages of the disease from muscular weakness and spasticity, and death often results from respiratory failure owing to muscle weakness. Although there is at present no cure,'4 much support and symptomatic treatment may be provided through multidisciplinary medical teams and voluntary organisations. These include management of spasticity, mobility, dysarthria, dysphagia, respiration, and psychosocial problems.
Linkage analysis and superoxide dismutase (SOD-1) mutations LINKAGE TO CHROMOSOME 21 The earliest evidence of linkage in FALS came from studies using restriction fragment length polymorphisms (RFLPs) when Siddique et al '5 mapped a FALS locus to chromosome 21 q22. 1. Multipoint analysis indicated that the locus was 10 cM distal to D21S58, but at this time no significant two point lod scores were obtained. Since then a number ofmicrosatellite markers have been identified in this region which give significant two point lod scores, for example, D21 S235, D2 1 S223, and D21 S224.
IDENTIFICATION OF SOD-1 MUTATIONS
Subsequent studies were carried out on a candidate in proximity to the FALS locus which was cytosolic copper zinc dependent superoxide dismutase (SOD-1). This is a well characterised enzyme which exists as a homodimer whose sequence of 153 amino acids is remarkably well conserved across species from man to plants, such as tomato, and microorganisms, such as yeast. The enzyme is present in virtually all animal cells and in man is especially highly concentrated in the liver, erythrocytes, and brain. A number of mutations were identified initially in two out of five of the exons encoding this protein. ' Support for the idea that the mutation may be associated with a gain of new function has come from transgenic studies in which mice from a Gly93Ala transgene but not an Ala4Val line that express the largest amounts of SOD enzyme activity in brain developed a syndrome "suggestive of MND". The disease was only in one line of mice and it is possible that the site of integration of the transgene may have contributed to disease development. Mice bearing the normal human SOD gene as well as the wild type murine SOD-1 do not develop neurodegeneration.41 As pointed out above, the mutation involved in this study, Gly93Ala, does not perturb enzyme activity to a significant level. Thus a gain of function mutation may have occurred in this case which is not associated with a reduction in SOD enzyme activity. Alternatively, only a minimal effect on enzyme activity may be sufficient to cause the disease.
SOD-1 is highly abundant in neurones accounting for up to 1% of the total protein. Most types of neurone possess similar levels of SOD-1 immunoreactive protein22 but differences are, however, seen when levels of SOD-1 mRNA are quantitated and in this case motor neurones are seen to possess very high levels of SOD-1 mRNA.22 Neurones with high concentrations of the enzyme which may be critically dependent on SOD-1 for protection against superoxide may potentially become susceptible targets for additional adverse effects of the protein. On the other hand the selective vulnerability of motor neurones in the disease may depend on another feature of motor neurones. One popular hypothesis is that the activation of nitric oxide synthase by N-methyl-D-aspartate (NMDA) glutamate receptors leads to the generation of nitric oxide (NO) which reacts readily with superoxide to produce the toxic species peroxynitrite, which in turn releases hydroxyl free radicals. 42 43 The simultaneous availability of both high levels of superoxide from reduced SOD-1 activity and NO from NMDA receptor activation provides the conditions giving rise to free radical damage which is localised to the nervous system.
SOD-1 MUTATIONS IN SPORADIC CASES OF ALS
The same SOD-1 mutation Ile 1 3Thr has been detected in three out of of 56 munities which has no effect on enzyme activity. However, although subjects heterozygous for the mutation do not develop FALS, a high proportion of homozygotes for the mutation (Asp9OAla) studied in four families were shown (10/14) to manifest the disease and a recessive mode of inheritance may be responsible for this form of the disease.27 The site of this mutation is distant from the active site in a region which is not highly conserved in evolution and would not be expected to have a major effect on enzyme activity.
Other disease loci OTHER FALS LOCI
There is no evidence of SOD-1 abnormalities in a proportion (up to 80%) of FALS families from linkage analysis, sequencing of SOD-1 exons, and assays of SOD-1 enzyme activity.4518 Currently the more extensive pedigrees in this group are being systematically screened by linkage analysis for other FALS loci in laboratories in North America and our own in the UK. Ideally this should be carried out with highly polymorphic di-, tri-, and tetranucleotide microsatellite polymorphisms distributed across the genome at 10 cM intervals. Once positive lod scores have been obtained, the region can then be saturated with closely spaced markers and the job of positional cloning begins, that is if the gene does not turn out to be i previously identified gene as happened with SOD-1.
EXCLUSION OF CANDIDATE GENES INVOLVED IN HANDLING FREE RADICALS
Alternative strategies which have proved successful in studies on Alzheimer's disease are to concentrate on candidate genes or risk factors where more of the smaller families may be used and the analysis carried out by sib pair analysis and related statistical methods. 47 ALS cases, only two of whom were homozygous mutants. We confirmed the conclusion that CNTF deficiency is not causally related to the disease in 52 separate familial cases taking advantage of the fact that this mutation results in the loss of a HaeIII site that can be detected in restriction enzyme digests of a region of the CNTF gene amplified by PCR using flanking primers. No mutant homozygotes were found in these UK families, 67% were normal homozygotes, and 33% were heterozygotes. 64 Other aspects of neurotrophic function may turn out to be more relevant to ALS treatment; while CNTF is present mainly in Schwann cells and a subpopulation of astrocytes, the receptor is more widely expressed in neuronal tissue. To date the therapeutic trials using CNTF have been largely ineffective,'4 but targeting drug treatment is still likely to present a major problem with this approach.
Diagnostic testing SOD-i TESTING: CAUTIONARY THOUGHTS
The identification of SOD-1 mutations in FALS received much publicity in the general press, some of which was reported accurately and some exaggerated. As a result public expectation was raised about the immediate benefits of diagnostic testing and treatment. 
